Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Operating Leases (2022 - 2025)

Gossamer Bio's Operating Leases history spans 4 years, with the latest figure at $4.4 million for Q4 2025.

  • For Q4 2025, Operating Leases changed 0.0% year-over-year to $4.4 million; the TTM value through Dec 2025 reached $4.4 million, changed 0.0%, while the annual FY2025 figure was $4.4 million, 0.0% changed from the prior year.
  • Operating Leases reached $4.4 million in Q4 2025 per GOSS's latest filing, down from $4.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $7.8 million in Q2 2022 to a low of $144000.0 in Q4 2023.
  • Average Operating Leases over 4 years is $4.1 million, with a median of $4.4 million recorded in 2024.
  • Peak YoY movement for Operating Leases: crashed 95.82% in 2023, then soared 2954.17% in 2024.
  • A 4-year view of Operating Leases shows it stood at $3.4 million in 2022, then plummeted by 95.82% to $144000.0 in 2023, then skyrocketed by 2954.17% to $4.4 million in 2024, then changed by 0.0% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Operating Leases are $4.4 million (Q4 2025), $4.6 million (Q3 2025), and $4.8 million (Q2 2025).